![](https://porib.com/wp-content/uploads/2021/06/clinical_therapeutics.jpg)
Moreno S, González J, Lekander I, Martí B, Oyagüez I, Sánchez-de la Rosa R, Casado MA
Effectiveness of Maraviroc Plus Optimized Background Therapy for Previously Treated Patients with R5 HIV-1 Infection From the Perspective of the Spanish Health Care System
Clin Therap. 2010;32(13):2232-45
![](https://porib.com/wp-content/uploads/2021/06/vacunas.jpg)
Picazo J, Méndez C, Oyagüez I, Casado MA, Guijarro P
Coste-utilidad de la incorporación de las nuevas vacunas antineumocócicas conjugadas al programa de vacunación de la comunidad de Madrid. Impacto sobre la enfermedad neumocócica invasora
Vacunas. 2010;11:96-104
![](https://porib.com/wp-content/uploads/2021/07/clinical_and_translational_oncology.jpg)
Frias C, Cortés J, Seguí MA, Oyagüez I, Casado MA
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain
Clin Transl Oncol. 2010;12(10):692-702
![](https://porib.com/wp-content/uploads/2021/06/applied_health_economics_and_health_policy.jpg)
Orofino J, Soto J, Casado MA, Oyagüez I
Global spending on orphan drugs in the main European markets (France, Germany, United Kingdom, Italy and Spain) during 2007
Appl Health Econ Health Policy. 2010;8(5):301-15
![](https://porib.com/wp-content/uploads/2021/06/progresos_de_obstetricia_y_ginecologia.jpg)
Castellsagué X, San Martín M, González A, Casado MA
Epidemiología de las lesiones precancerosas y verrugas genitales asociadas a infección por virus del papiloma humano en España
Progresos de Obstetricia y Ginecología. 2010;53(3):81-7
![](https://porib.com/wp-content/uploads/2021/06/bone_marrow_transplantation.jpg)
De la Cámara R, Jarque I, Sanz MA, Grau S, Casado MA, Sabater FJ, Carreras E